Dentists and other dental healthcare personnel could be at risk of developing idiopathic pulmonary fibrosis at work, the U.S.
Articles by Patricia Inácio, PhD
Cells present in the outer rims of small blood vessels in the lung, called pericytes, convert from a healthy state…
Looking at pulmonary fibrosis (PF) as an age-related disease and working with a gene therapy that lengthens the life of lung cells, researchers report that they were able to lessen — and even stop — lung fibrosis in mice. “This is the first time that pulmonary fibrosis has been treated as an age-related disease, looking for rejuvenating the affected tissues,” Maria A. Blasco, study's lead author and group leader at the Spanish National Cancer Research Centre (CNIO), in Madrid, said in a press release. The study “Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres” was published in the journal eLife.
Advanced Interactive Response Systems (AIRS), Owlstone Medical and patientMpower are the three winners of the $1 million IPF Catalyst…
A project that aims to develop a new system to deliver therapies specifically to the lungs of patients with…
Researchers identified a molecular pathway called ER stress, and a molecular factor known as PI3K, as promoters of pulmonary fibrosis…
Health Canada has issued a safety warning on Boehringer Ingelheim’s idiopathic pulmonary fibrosis therapy Ofev (nintedanib) after patients in a…
Bellerophon Therapeutics has enrolled the first pulmonary hypertension patient in a Phase 2b clinical trial of its INOpulse nitric oxide…
Throughout 2017, Pulmonary Fibrosis News Today reported daily discoveries, therapeutic developments, and events related to pulmonary fibrosis. Here, we review…
A factor called Krüpple-like-factor 4, or KLF4, treated lung fibrosis in a mouse model of idiopathic pulmonary fibrosis (IPF) by…